Show simple item record  

dc.contributor.authorLao, Chunhuanen_NZ
dc.contributor.authorLawrenson, Rossen_NZ
dc.contributor.authorEdwards, Melissaen_NZ
dc.contributor.authorCampbell, Ianen_NZ
dc.date.accessioned2019-09-24T22:58:21Z
dc.date.available2019-09-01en_NZ
dc.date.available2019-09-24T22:58:21Z
dc.date.issued2019en_NZ
dc.identifier.citationLao, C., Lawrenson, R., Edwards, M., & Campbell, I. (2019). Treatment and survival of Asian women diagnosed with breast cancer in New Zealand. Breast Cancer Research and Treatment, 177(2), 497–505. https://doi.org/10.1007/s10549-019-05310-zen
dc.identifier.issn0167-6806en_NZ
dc.identifier.urihttps://hdl.handle.net/10289/12917
dc.description.abstractPurpose This study aims to examine the differences in characteristics, treatment and survival between Asian and European women diagnosed with stage I–III breast cancer in New Zealand. Methods The studied population included European women and Asian women diagnosed with stage I–III breast cancer between June 2000 and May 2013 identified from the combined Waikato and Auckland Breast Cancer Registers. Characteristics and treatment were compared between Asian and European women. Kaplan–Meier method was used to examine the survival difference. Cox proportional hazards model was used to estimate the hazard ratio (HR) of mortality. Results The studied cohort included 8608 European and 949 Asian women. Asian women were younger, had less comorbidities and were less likely to be obese than European women. Asian women were more likely to have grade 3, larger and HER2+  breast cancers. Asian women were more likely to receive mastectomy, less likely to have reconstruction after mastectomy, less likely to have chemotherapy, less likely to be treated with trastuzumab if HER2+, and had better adherence to endocrine therapy (adjusted odds ratio: 1.54; 95% CI 1.22–1.93). Asian women had better cancer-specific survival and all-cause survival than European women. The adjusted HR of cancer-specific mortality and all-cause mortality were 0.64 (95% CI 0.49–0.82) and 0.68 (95% CI 0.55–0.84), respectively. Conclusions Asian women are more likely to have high grade, larger and HER2+ breast cancers than European women. In spite of this, they had better breast cancer outcomes. Possible explanations include the differences in adherence to endocrine therapy, age, BMI and comorbidities.
dc.format.mimetypeapplication/pdf
dc.language.isoenen_NZ
dc.publisherSpringeren_NZ
dc.rights© 2019 Springer.This is the author's accepted version. The final publication is available at Springer via dx.doi.org/10.1007/s10549-019-05310-z
dc.subjectScience & Technologyen_NZ
dc.subjectLife Sciences & Biomedicineen_NZ
dc.subjectOncologyen_NZ
dc.subjectAsian womenen_NZ
dc.subjectBreast canceren_NZ
dc.subjectAdherence to endocrine therapyen_NZ
dc.subjectSurvivalen_NZ
dc.subjectEthnic disparityen_NZ
dc.subjectETHNIC-DIFFERENCESen_NZ
dc.subjectDISPARITIESen_NZ
dc.subjectADHERENCEen_NZ
dc.subjectCOMORBIDITYen_NZ
dc.subjectMANAGEMENTen_NZ
dc.subjectMORTALITYen_NZ
dc.subjectAMERICANSen_NZ
dc.subjectSUBTYPESen_NZ
dc.subjectBIOLOGYen_NZ
dc.subjectRISKen_NZ
dc.titleTreatment and survival of Asian women diagnosed with breast cancer in New Zealanden_NZ
dc.typeJournal Article
dc.identifier.doi10.1007/s10549-019-05310-zen_NZ
dc.relation.isPartOfBreast Cancer Research and Treatmenten_NZ
pubs.begin-page497
pubs.elements-id237706
pubs.end-page505
pubs.issue2en_NZ
pubs.publication-statusPublisheden_NZ
pubs.volume177en_NZ
dc.identifier.eissn1573-7217en_NZ


Files in this item

This item appears in the following Collection(s)

Show simple item record